BNB Plus Corp., formerly Applied DNA Sciences, Inc., is a digital asset treasury (DAT) company that has adopted BNB, the native cryptocurrency of the Binance blockchain ecosystem, as its primary reserve asset. Its segments include digital asset treasury, therapeutic deoxyribonucleic acid (DNA) production services, DNA tagging and security products and services. Its digital asset treasury segment is engaged in managing digital assets. Its therapeutic DNA production services segment is engaged in nucleic-acid production solutions for the biopharmaceutical and diagnostics industries, including LineaDNA, LineaRNAP and LineaIVT. Its DNA tagging and security products and services segment is engaged in the manufacture and detection of DNA for industrial supply chains and security services. Its subsidiary LineaRx, Inc., is engaged in commercializing nucleic acid production solutions for the biopharmaceutical and diagnostics markets.

Employees

Sector

Investment Management & Fund Operators

More about the company

07-16	BNB Plus Corp.(OTCPK:BNBX) dropped from S&P TMI Index	CI
07-13	BNB Plus Receives Nasdaq Delisting Notice, Plans OTC Listing	MT

Market Cap	612K 537K 500K 459K 862K 58.91M 875K 5.93M 2.32M 28.96M 2.3M 2.25M 100M	P/E 2024 *	-	P/E 2025	-0.03x
Enterprise Value	-863K -758K -705K -647K -1.22M -83.09M -1.23M -8.37M -3.27M -40.85M -3.24M -3.17M -141M	EV / Sales 2024	0.29x	EV / Sales 2025	1.65x
Free-Float	90.59%	Yield 2024 *	-	Yield 2025	-

07-16	BNB Plus Corp.(OTCPK:BNBX) dropped from S&P TMI Index	CI
07-13	BNB Plus Receives Nasdaq Delisting Notice, Plans OTC Listing	MT
07-12	BNB Plus Corp.(OTCPK:BNBX) dropped from NASDAQ Composite Index	CI
05-25	BNB Plus Corp. announced that it expects to receive $5 million in funding from Silvermine Capital Advisors, LLC, Off The Chain Capital, LLC	CI
05-15	BNB Plus Corp. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
04-21	BNB Plus Corp Announces Review of Strategic Alternatives to Maximize Shareholder Value	CI
03-25	Comstock MultiChain Fund, L P Engages with BNB Plus Corp	CI
02-12	BNB Plus Corp. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
02-05	BNB Plus Corp. Appoints James Haft as Independent Director and Nominating Committee Member, Effective February 2, 2026	CI
01-22	BNB Plus Corp. Announces Resignation of Director Elizabeth M. Schmalz Shaheen, Effective January 15, 2026	CI
01-05	BNB Plus Corp. Receives USD 1.2 Million Accelerated LineaDNA? Order	CI
01-05	Bnb Plus Corp receives $1.2M Accelerated Lineadna(TM) order	RE
12-22	BNB Plus Corp. Reports Earnings Results for the Full Year Ended September 30, 2025	CI

10/06/24	HC Wainwright Adjusts Applied DNA Sciences Price Target to $1.50 From $7, Maintains Buy Rating	MT
14/05/24	Maxim Downgrades Applied DNA Sciences to Hold From Buy	MT
08/12/23	HC Wainwright Cuts Price Target on Applied DNA Sciences to $2 From $4, Keeps Buy Rating	MT
14/08/23	HC Wainwright Adjusts Price Target on Applied DNA Sciences to $4 From $5, Keeps Buy Rating	MT
15/12/22	HC Wainwright Trims Price Target on Applied DNA Sciences Inc to $5 From $8, Maintains Buy Rating	MT

07-13	BNB Plus Corp. (BNBX) Announces Nasdaq Delisting Determination and Transition to OTCQB Market; Company to Seek Review by Nasdaq Listing and Hearing Review Council	BU
05-26	BNB Plus Corp. (BNBX) Secures Initial Commitments for $4.1M in Strategic Financing	BU
05-15	BNB Plus: Fiscal Q2 Earnings Snapshot	AQ
04-23	BNB Plus Corp. Completes Historic $1.2 Million LineaDNA™ Order	BU
04-20	BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value	BU

Applied DNA Sciences Inc Share Price OTC Bulletin Board

Stocks

US03815U1025

Investment Management & Fund Operators

Valuation: Applied DNA Sciences Inc

Latest news : Applied DNA Sciences Inc

Analysts' recommendations: Applied DNA Sciences Inc

Press Releases: Applied DNA Sciences Inc

News in other languages: Applied DNA Sciences Inc

Managers and Directors: Applied DNA Sciences Inc

Investment Management

Financials

Company Profile

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

02/03/20	Applied DNA Sciences : informe des avancées de la collaboration avec Takis Biotech concernant le COVID-19 et de la conception de 4 candidats vaccins LinearDNA™ au stade préclinique
02/03/20	Aktuelle Meldung von Applied DNA Sciences zur COVID-19-Kooperation mit Takis Biotech: vier präklinische LinearDNA™-Impfstoffkandidaten entwickelt
29/10/18	Applied DNA Sciences : GHCL, un acteur mondial du linge de maison, crée "CIRKULARITY", une plateforme de marques inspirée par le linge de lit "REKOOP" en polyester recyclé durable et traçable
29/10/18	Applied DNA Sciences : GHCL, azienda internazionale di tessuti per la casa, crea “CIRKULARITY”, una piattaforma di marchi ispirata da “REKOOP”, biancheria in poliestere riciclato, sostenibile e tracciabile
29/10/18	Applied DNA Sciences : GHCL, weltweiter Anbieter von Heimtextilien, gründet die Markenplattform „CIRKULARITY“, inspiriert von „REKOOP“, der Lösung für nachhaltige, rückverfolgbare, recycelte Polyester-Bettwäsche

Manager	Title	Age	Since
Clay Shorrock CEO	Chief Executive Officer	43	28/09/2025
Beth Jantzen DFI	Director of Finance/CFO	49	14/02/2015
Patrick Horsman CIO	Chief Investment Officer	47	30/09/2025

Director	Title	Age	Since
Yacov Shamash BRD	Director/Board Member	76	16/03/2006
Bob Catell BRD	Director/Board Member	89	06/10/2016
James Haft BRD	Director/Board Member	64	01/02/2026

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BLACKSTONE INC.	+3.73%	+1.60%	-27.61%	+22.65%	97.79B
KKR & CO. INC.	+2.88%	-2.15%	-34.24%	+62.52%	86.17B
ARES MANAGEMENT CORPORATION	+2.93%	-0.92%	-31.71%	+23.94%	27.35B
AMUNDI	0.00%	-1.96%	+21.94%	+52.53%	20.23B
FRANKLIN RESOURCES, INC.	+0.39%	-0.63%	+31.17%	+9.80%	16.78B
THE CARLYLE GROUP INC.	+2.00%	-1.49%	-27.16%	+31.51%	15.99B
PERSHING SQUARE INC.	+0.55%	-1.62%	-	-	13.5B
ARES CAPITAL CORPORATION	+0.83%	-2.11%	-18.52%	-4.36%	13.36B
SBI FUNDS MANAGEMENT LIMITED	+1.71%	0.00%	-	-	12.14B
Average	+1.67%	-3.30%	-12.30%	+28.37%	33.7B
Weighted average by Cap.	+2.54%	-4.15%	-22.45%	+35.76%

	2024	2025
Net sales	3.43M 3.01M 2.8M 2.57M 4.83M 330M 4.91M 33.28M 13M 162M 12.88M 12.6M 562M	2.14M 1.88M 1.75M 1.6M 3.01M 206M 3.06M 20.73M 8.1M 101M 8.02M 7.85M 350M
Net income	-6.99M -6.14M -5.71M -5.24M -9.85M -673M -10M -67.82M -26.5M -331M -26.25M -25.68M -1.14B	-15.16M -13.32M -12.38M -11.36M -21.35M -1.46B -21.68M -147M -57.45M -718M -56.91M -55.69M -2.48B
Net Debt	-5.69M -5M -4.65M -4.27M -8.02M -548M -8.14M -55.21M -21.57M -269M -21.37M -20.91M -932M	-1.47M -1.3M -1.2M -1.11M -2.08M -142M -2.11M -14.3M -5.59M -69.81M -5.54M -5.42M -241M